A phase 3 Randomised Doubleblind, placebo controlled study Evaluating the efficacy and safety of Idelalisib (GS-1101) in combination with Bendamustine and Rituximab for previously Treated Indolent Non

Project: Research

StatusFinished
Effective start/end date1/07/1330/11/14